The mechanism of action of botulinum neurotoxin type A (BoNT/A) is well characterized, but some published evidence suggests the potential for neuronal retrograde transport and cell-to-cell transfer (transcytosis) under certain experimental conditions. The present study evaluated the potential for these processes using a highly selective antibody for the BoNT/A-cleaved substrate signal in distal muscles and associated SC regions without evidence for transcytosis, suggesting that the staining was due to systemic spread of the toxin. Despite this spread, functional effects were not detected in the distal muscles. Therefore, under the present experimental conditions, our results suggest that BoNT/A is confined to MNs and any evidence of distal activity is due to limited systemic spread of the toxin at higher doses and not through transcytosis within SC.
INTRODUCTION
Botulinum neurotoxin type A (BoNT/A) is used clinically for a growing number of indications including disorders involving skeletal and smooth muscle, glands and nociceptive pain mechanisms (Aoki and Francis, 2011; Brin, 2009) . The primary reasons for the increased therapeutic application of BoNT/A is attributed to its marked clinical efficacy and proven safety record (Simpson et al., 2016) . The general mechanism of action (MoA) for BoNT/A has been established (Montal, 2010; Rossetto et al., 2014) and involves a . Functionally, this mechanism leads to the from nerve fiber endings and subsequent transient paralysis or quiescence of the associated end-organ being innervated (Dolly and Lawrence, 2014) . Results from decades of clinical usage have confirmed this peripheral action of BoNT/A (Simpson et al., 2016) Recent studies have proposed that BoNT/A catalytic activity is not strictly confined to presynaptic terminals at the peripheral site of injection. These investigations have indicated that at higher doses, BoNT/A activity can spread to central neurons via a mechanism of retrograde transport within first-order neurons followed by transfer (transcytosis) of the active toxin to second-order neurons where it can potentially cleave SNAP25 and inhibit transmitter release Mazzocchio and Caleo, 2014) . While it was reported that only a fraction of the total internalized BoNT/A actually undergoes retrograde transport and transcytosis (Restani et al., 2012a) , it was proposed that this fraction utilizes similar mechanisms to those exploited by tetanus neurotoxin (TeNT) to gain access to central neurons (Bercsenyi et al., 2013; Bomba-Warczak et al., 2016; Lalli et al., 2003) . Consequently, it was hypothesized that peripheral applications of BoNT/A can directly transcytose to neurons within the central nervous system (CNS; (Mazzocchio and Caleo, 2014) .
Nonetheless, questions have been raised regarding the tools, models and BoNT/A dosing levels utilized in these studies (Lawrence et al., 2012) . For example, these studies relied on a rabbit polyclonal antibody (pAb) to detect SNAP25 197 in BoNT/A-treated samples using both Western Blot and immunohistochemical (IHC) assays (Antonucci et al., 2008; Matak et al., 2011; Matak et al., 2012; Restani et al., 2011; Restani et al., 2012b) . The SNAP25 197 -positive staining observed in these studies was purported as indicative of the presence of active BoNT/A in both first-order and second-order neurons.
We recently developed site-specific, recombinant monoclonal antibodies (rMAb) against the BoNT/A-cleaved SNAP25 epitope and demonstrated their superior specificity over pAbs and other commercial monoclonal antibodies at recognizing SNAP25 197 , especially with regards to IHC (Rheaume et al., 2015) . Since many of the conclusions regarding BoNT/A retrograde transport and transcytosis were based on IHC analysis of the cleaved product, we resolved to explore this possibility utilizing one of our rMAbs (Ab632) in combination with high-resolution three-dimensional (3D) imaging and quantitative analysis to characterize SNAP25 197 expression in a rat motor neuron (MN) pathway, following intramuscular (i.m.) BoNT/A injections at various doses. We performed a systematic evaluation to determine whether SNAP25 197 is confined to primary MNs or is also found in neighboring cells and/or nerve fibers within the spinal cord (SC). We selected the motor pathway leading from the rat hindlimb tibialis anterior (TA) muscle through the sciatic nerve and into the L4-L5 segment of the ventrolateral SC (VLSC). This anatomical pathway represents a relevant, in vivo system to study the effects of BoNT/A, as motor nerve terminals (MNT) are the target of numerous therapeutic indications.
To accurately carry out this analysis, it was necessary to understand and appreciate the complex motor circuitry within the VLSC (Figure 1 ). MNs have extensive dendritic arbors that extend radially from the soma in all axes (i.e., mediolateral, dorsoventral and rostrocaudal), often reaching the dorsal SC (Cook and Woolf, 1985; Kurz et al., 1990) . Furthermore, MN dendritic branches form a multitude of synaptic contacts with neighboring neurons and nerve fibers, including Renshaw cells (Alvarez and Fyffe, 2007) , excitatory and inhibitory interneurons (Kiehn, 2006; Nishimaru and Kakizaki, 2009 ), sensory afferents (Snider et al., 1992) and descending catecholamine fibers (Han et al., 2007; Sharples et al., 2014) , as well as resident glial cells (Blackburn et al., 2009 ) that collectively serve to modulate sensorimotor signals to the muscle (Hall, 2004) . Under the present experimental conditions, our results suggest that BoNT/A is confined to MNs and any evidence of distal activity is due to limited systemic spread of the toxin at higher doses and not through transcytosis within the SC. 
EXPERIMENTAL PROCEDURES

Materials
Animals
Male Sprague-Dawley rats (225-250g; Charles River, Wilmington, MA) were group housed on a 12 hour light-dark cycle with food and water available ad libitum. A total of ~60 Sprague-Dawley rats were used for this study. Animal protocols and procedures were approved by the Allergan Institutional Animal Care and Use Committee and followed National Institutes of Health guidelines for the care and use of laboratory animals.
BoNT/A preparation and injection procedures
Working solutions of BoNT/A (onabotulinumtoxinA, 900 kDa complex, Allergan, plc., Irvine, CA) were prepared in 0.9% saline. For single-injection studies, 20µl of BoNT/A (3, 10, 30 U/kg) in 0.9% saline or AF-488 conjugated CTB (10 µg/kg) was injected intramuscularly (i.m.) into the mid-belly of the TA muscle of the right hindlimb. Doses of BoNT/A utilized were equivalent to ~22, 75 and 225 pg/kg, respectively (based on 150 kDa BoNT/A neurotoxin protein). Rats were sacrificed at 1, 3 or 6 days post-BoNT/A injection. For multi-injection studies, CTB AF-488 was first injected into five equidistant spots spanning the right TA rat muscle (10 µg/kg, 10 µl each). The following day, BoNT/A (10 U/kg) was injected into the midbelly of the muscle. All animals were sacrificed 6 days post-BoNT/A injection. Separate control animals received saline injections into the right TA muscle.
Digit abduction score assay
The Digit Abduction Score (DAS) assay was performed as previously outlined (Broide et al., 2013) . Rats were scored for DAS response starting at 24 hr following onabotulinumtoxinA injections by eliciting hind limb digit abduction. DAS response was induced by grasping the rat around the torso, lifting into the air and simulating a drop or a return to a flat surface. The rat reflexively braces for impact by spreading the digits in its hind paws and the DAS response was immediately scored with the animal facing up in a reclining position. The varying degrees of digit abduction were then scored on a five-point scale (0 = normal to 4 = maximum reduction in digit abduction). The peak DAS responses at each dose, which occurred on days 3-4 were observed and recorded.
Tissue preparation and immunohistochemistry
We utilized both perfused/post-fixed as well as fresh/post-fixed neuronal tissue. The former was best for anatomical preservation of nerve fiber morphology within the SC, while the latter was necessary for double-labeling experiments in order to preserve the CTB AF-488 signal and other sensitive antigens. At scheduled time-points, rats were either anesthesized and transcardially perfused with 4% paraformaldehyde (for fixed tissue) or euthanized with CO 2 (for fresh-frozen tissue). Ipsilateral and contralateral TA muscles, sciatic nerves, lumbar and thoracic SC segments (T9-L5; ~1.2 cm) were then harvested and either OCT-embedded and frozen in liquid nitrogen, or post-fixed in 4% paraformaldehyde for 2 hours, immersed in 30% sucrose and OCT-embedded at -20°C. All tissues were stored at -80°C until use.
Tissues were cryostat-sectioned into 12, 16, or 40 µm-thick sections, mounted onto microscope slides and post-fixed with 4% paraformaldehyde for 10 min (for fresh-frozen tissue) followed by a wash in PBS. Slide-mounted sections were first blocked for non-specific signal in blocking buffer (1X PBS + 5% Normal Donkey Serum) for 1h and then incubated with primary antibodies at desired concentrations in blocking buffer overnight at 4°C. Following several washes, sections were incubated with Alexa Fluor-labeled secondary antibodies (Jackson ImmunoResearch, West Grove, PA) diluted in blocking buffer for 2 hr at room temperature and washed again. Slide-mounted sections were coverslipped using ProLong Gold Antifade Mountant with DAPI (Life Technologies, Grand Island, NY). Adjacent sections processed without primary antibodies served as negative controls to show background signal. Tissues from saline-treated animals were also analyzed to identify any non-specific signal from the primary antibody.
Image acquisition and analysis
Muscle, sciatic nerve and spinal cord images were acquired and analyzed using either an 
Statistical analysis
All data were analyzed using Excel (Microsoft, Redmond, WA) and statistical evaluation was performed, where needed using SigmaPlot v12.5 (Systat Software Inc., San Jose, CA). After analysis for the normal distribution and equal variance among values from the same set, statistical significance was determined using a non-parametric test (Kruskal-Wallis one-way ANOVA on ranks followed by Dunn's post-hoc analysis to correct for multiple comparisons).
Sample number (N) represents the number of animals, where in each case, multiple images were analyzed (as indicated above). Data are shown as mean ± SEM, with p ≤ 0.05 considered to be a significant difference.
RESULTS
Parameters governing SNAP25 197 expression along motor pathways
To characterize the expression of SNAP25 197 in motor pathways following peripheral BoNT/A administration, preliminary studies were performed to establish parameters for visualizing SNAP25 197 -IR signal, particularly around the TA-MN pool residing in L4-L5 region of VLSC. First, a dose-ranging study was implemented to determine the pattern and intensity of SNAP25 197 -IR staining at different BoNT/A dosing levels. We started with two, relatively low doses of BoNT/A (3 and 10 U/kg) that were previously shown to have partial to full muscle paralysis as measured by the DAS assay (Broide et al., 2013) . A higher, saturating dose of toxin intensity from 1-to 3-days post-injection and ~20-fold increase from 1-to 6-days post-injection (Table 1) . Thus, waiting 6-days post-BoNT/A injection at a 30 U/kg dose yielded robust and optimal SNAP25 197 -IR signal in the VLSC for analysis of its distribution.
Distal spread of BoNT/A activity at saturating dose
Having established these parameters, we injected 30 U/kg BoNT/A i.m. into the right TA.
At 6-days following injection, the following tissues were harvested and processed for IHC staining with our anti-SNAP25 197 selective rMAb: ipsilateral and contralateral TA muscle, contralateral forelimb extensor muscles, the mid-portion of ipsilateral and contralateral sciatic nerves and L4-L5, L1-L2 and T9-T10 segments of SC. In the ipsilateral TA, SNAP25 197 -IR signal was clearly observed in all visible MNTs and axons, adjacent to α-Bgt-labeled nicotinic acetylcholine receptor (nAChR) clusters ( Figure 3A ). SNAP25 197 -IR was also observed along the length of a small number of axons within the ipsilateral sciatic nerve ( Figure 3C ). Furthermore, in the L4-L5 segment of SC, a diffuse circular pattern of SNAP25 197 -IR signal was clearly visible in the ipsilateral VLSC region corresponding to laminae IX, the area containing cholinergic MNs that innervate the TA muscle ( Figure 3E (Chen et al., 1999) . SNAP25 197 -IR staining in distal regions of the SC was not detected following i.m. injections of either 10 (data not shown) or 3 U/kg of BoNT/A ( Figure 5D ). Tissues from saline-treated animals showed very low levels of background staining (data not shown).
Colocalization of SNAP25 197 -IR with biomarkers for cholinergic motor neurons
Since the primary SNAP25 197 -IR signal was concentrated in the ipsilateral L4-L5 VLSC region containing MNs projecting to the TA muscle of injection, we sought to examine whether this signal was localized exclusively to MNs or also found within neighboring neurons. Initially, colocalization of SNAP25 197 -IR signal with MNs was investigated by immuno-staining for two cholinergic biomarkers to define the MNs (Figure 1B 
No colocalization of SNAP25 197 -IR with biomarkers for neighboring cells and nerve fibers
While some SNAP25 197 -IR staining was colocalized with cholinergic biomarkers for MNs, a large portion of this staining, mostly in neurite processes was not ( Figure 6 ). We therefore sought to determine whether SNAP25 197 -IR staining was also localized to neighboring neurons and/or nerve fibers having synaptic contacts with the MNs. Using immunofluorescence labeling of specific biomarkers to identify each of these neighboring cell-and nerve fiber-types ( Figure 1B) , we looked for colocalization of SNAP25 197 -IR with these biomarkers in the L4-L5 VLSC region. Glutamatergic synaptic contacts from both sensory afferents (Rotterman et al., 2014; Snider et al., 1992) and excitatory interneurons (Brumovsky et al., 2007; Malet et al., 2013) , delineated by vGlut1 and vGlut2 showed no colocalization with SNAP25 197 -IR staining ( Figure 7A, B) . Likewise, synaptic contacts from inhibitory interneurons (Nishimaru and Kakizaki, 2009; Nishimaru et al., 2011) delineated by staining for glutamic acid decarboxylase (GAD65/67) showed no colocalization with SNAP25 197 -IR staining ( Figure 7C ). Furthermore, Renshaw cells, identified by labeling for calbindin D28k (Arvidsson et al., 1992; Carr et al., 1998) , showed no colocalization with SNAP25 197 -IR staining ( Figure 7D ). Descending spinal pathways play an important role in modulating locomotor networks in the VLSC via catecholamine signaling (Fung et al., 1994; Sharples et al., 2014) and can be delineated by staining for tyrosine hydroxylase (TH). These nerve fibers showed no colocalization with SNAP25 197 -IR staining ( Figure 7E ). Finally, astrocytes, identified by labeling for glial fibrillary acidic protein (GFAP) showed no colocalization with SNAP25 197 -IR staining ( Figure 7F ).
The colocalization of SNAP25 197 -IR staining with each biomarker was further examined by 3D image analysis and for brevity, the analysis is herein presented only for calbindin D28k (Figure 7G-I) . In many regions surrounding the MNs, the signals for SNAP25 197 
Colocalization of SNAP25 197 -IR with a retrograde tracer for the motor pathway
To further demonstrate whether SNAP25 197 -IR staining was confined to the primary MNs following intramuscular BoNT/A injection, an alternate method was employed to better delineate the MNs using retrograde tracing with fluorescent-labeled cholera toxin B subunit (CTB). CTB has been utilized for tracing neuronal pathways in vivo because of its natural ability to bind to presynaptic terminals, become endocytosed and retrogradely transported to the endoplasmic reticulum and other parts of the cell (Lai et al., 2015; Viswanathan et al., 2009) . In preliminary experiments, we found that single injections of Alexa-Fluor 488-CTB (10 ug/kg) into the midbelly of the TA only permeated ~37% of all TA-MNTs compared to ~96 and ~99% permeation of MNTs with 3 and 10 U/kg BoNT/A, respectively (as identified by SNAP25 197 -IR staining).
Furthermore, only a small fraction of MNs and their dendritic arborization within ipsilateral VLSC were labeled following a single injection of labeled-CTB into the TA ( Figure 8D ).
Thus, to help balance the extent of signal expression for both markers in the VLSC, labeled-CTB was injected into five equidistant spots spanning the right TA, followed one day later by a single injection of BoNT/A at a lower dose (10 U/kg) into the mid-belly of the TA. 6-days following BoNT/A injection (7-days following CTB injections), a larger population of MNs along with their dendritic arborization were clearly delineated by labeled-CTB in ipsilateral VLSC ( Figure 8A ). This signal directly corresponded to SNAP25 197 -IR staining within the same SC region ( Figure 8B ) and showed a larger degree of colocalization than demonstrated with the cholinergic biomarkers ( Figure 8C) . Surprisingly, upon closer examination of the signal within the VLSC, we discovered that on the whole, labeled-CTB and SNAP25 197 -IR signals were expressed in adjacent intracellular compartments within the MNs ( Figure 8E ). While labeled-CTB was localized primarily within the cellular cytoplasm ( Figure 8F ), SNAP25 197 -IR staining was largely expressed on the cellular membrane ( Figure 8G) . Moreover, the majority of colocalization between these two signals was found close to the cell membrane ( Figure 8H and I).
SNAP25 197 is localized on the motor neuron plasma membrane
To determine whether SNAP25 197 is localized to the plasma membrane and possibly within synaptic regions of MNs, we used high-resolution 3D imaging to examine SNAP25 197 -IR staining and its potential colocalization with three putative synaptic biomarkers; two representative markers of the SNARE family of proteins (SNAP25 206 and syntaxin) and one specific to cholinergic synapses (VAChT; Figure 9 ). While SNAP25 206 was ubiquitously expressed throughout the VLSC, SNAP25 197 -IR was found colocalized with SNAP25 206 -IR on the plasma membrane of MNs at 6-days post-BoNT/A treatment ( Figure 9A-C) . Additionally, SNAP25 197 -IR colocalized with syntaxin-IR ( Figure 9D-F) , a SNARE protein that partners with SNAP25 206 Rizo and Sudhof, 2002) . Finally, SNAP25 197 -IR was also found to be highly colocalized with VAChT-IR around the MN plasma membrane and within the cytoplasm, as shown previously ( Figure 9G-I ). These data demonstrate that the majority of BoNT/A-cleaved SNAP25 is localized to the plasma membrane of MNs, potentially at regions of synaptic contact.
DISCUSSION
In the present study, the expression of BoNT/A-cleaved substrate (SNAP25 197 ) was characterized in a rat MN pathway following toxin i.m. injections to determine whether SNAP25 197 is confined to MNs or also found in neighboring cells or nerve fibers within the SC. Previous studies have suggested that BoNT/A enzymatic activity can spread from presynaptic peripheral terminals to central neurons via retrograde transport within first-order neurons followed by transcytosis of active toxin to second-order neurons where it can potentially cleave SNAP25 and inhibit transmitter release, similar to the mechanism outlined for tetanus toxin (Antonucci et al., 2008; Mazzocchio and Caleo, 2014; Restani et al., 2011; Restani et al., 2012b) . Additional investigations have extended this concept of central BoNT/A activity to include the application to sensory and motor pathways (Matak et al., 2011; Matak et al., 2012) . A more recent publication using hippocampal neurons grown in microfluidic chambers also proposed that BoNT/A can exert its effects on both first-and secondorder neurons (Bomba-Worczak, 2016) . While these studies have presented an extensive set of data, their results should be examined within the context of their tools, models and BoNT/A dosing levels, which may explain the different conclusions drawn. For example, the aforementioned studies have relied on a rabbit polyclonal antibody (pAb) to detect SNAP25 197 in BoNT/A-treated samples using both Western Blot and IHC assays.
This antibody was also used in other investigations for IHC with mixed results (Marinelli et al., 2012; . Recently, we compared antibodies for site-specific detection of the SNAP25 197 epitope and demonstrated greater specificity of our rMAbs over pAbs and other commercial monoclonal antibodies, especially with regards to IHC analysis (Rheaume et al., 2015) . The subsequent findings from our current study suggest that conclusions made regarding BoNT/A activity may depend greatly on the antibodies being used.
Another example regarding the IHC analysis from the previous studies relates to their quantitative colocalization of biomarkers. Investigators examining the 2D quantitative colocalization of SNAP25 197 with various biomarkers within rat tectum following intraocular BoNT/A injections demonstrated significant colocalization of this cleaved substrate with biomarkers for neighboring synaptic terminals (Restani et al., 2011) . They concluded that BoNT/A had undergone transcytosis within the optic tectum. Our quantitative colocalization found similar levels of SNAP25 197 colocalized with biomarkers for second-order neurons within the VLSC. However, upon high-resolution 3D analysis of the staining patterns, we observed that these signals were actually in two distinct, but closely adjacent neuronal compartments (i.e., 2 separate neurons). These results indicate that quantitative IHC colocalization of biomarkers in the CNS (especially on a 2D level) may be difficult to interpret because the physical area of the signal (e.g., a synapse) is often smaller than the light diffraction limit. Thus, our data demonstrate that colocalization of biomarker IR-staining within tissues must ultimately be determined using precise 3D analysis of the signals.
Many earlier studies also used relatively high doses of BoNT/A for extended periods of time compared to the present study. Doses employed by these investigators, often ≥1 ng/kg BoNT/A (150 kDa protein), were well above the dose range (~1 -30 U/kg; equivalent to ~7.5 -225 pg/kg of 150 kDa BoNT/A) used to elicit muscle paralysis in animal physiological studies (Aoki, 1999; Broide et al., 2013) . Moreover, treatments were generally applied to fairly small compartments, resulting in a greater apparent local concentration. By comparison, the lower BoNT/A doses used in the current study (3 and 10 U/kg), demonstrating partial to full muscle paralysis in the DAS assay, are within the physiologically relevant dose range (Broide et al., 2013) . At these lower doses, BoNT/A was reasonably confined to the muscle of injection and the substrate-cleaving activity was limited to the ipsilateral MNs innervating the muscle. Moreover, very little to no SNAP25 197 -IR staining was detected in distal muscles or SC regions. Conversely at the higher, saturating dose of toxin (30 U/kg), we observed sporadic SNAP25 197 -IR staining in distal muscles and SC regions that was isolated with no neural connection to the ipsilateral L4-L5 VLSC. Indeed, our dosing paradigm is equivalent to that utilized by Matak and colleagues who observed similar SNAP25 197 staining patterns in the ventral SC with no clear evidence for transcytosis (Matak et al., 2012) . Altogether, these examples emphasize the need for highly sensitive tools, models and physiologically relevant dosing levels in order to characterize BoNT/A trafficking patterns and general MoA.
Systemic spread of BoNT/A at saturating doses
Our data suggest that at saturating doses, BoNT/A can exit the muscle of injection possibly through lymphatic drainage (May and Whaler, 1958) , ultimately reaching the systemic circulation. Once there, the toxin is distributed systemically to distal muscles where it can enter MNTs, cleave SNAP25 206 and then SNAP25 197 -IR staining may appear in the associated MNs and their dendritic processes. The resulting low levels of substrate cleavage may not necessarily result in measurable physiological paralysis of the distal muscles (i.e., via DAS assay), but may still exhibit altered MNT transmission, which can potentially be detected by a more sensitive assay, such as compound muscle action potential (Torii et al., 2014) . Physical spread of BoNT from the site of injection to distal muscles has been documented in preclinical studies and is determined by such factors as dosage and volume of injection (Arezzo, 2009; RamirezCastaneda et al., 2013) . Thus, the preclinical observation of BoNT/A activity in distal muscles and SC regions can be attributed to systemic spread of the toxin, particularly at high doses, as opposed to spread of toxin through transcytosis (Figure 1) .
Moreover, the lack of SNAP25 197 -IR signal in neighboring neurons needed to support the hypothesis for transcytosis reinforces the concept of systemic spread of BoNT/A at saturating doses.
BoNT/A-cleaved SNAP25 is confined to primary motor neurons and localized on the plasma membrane
While the results from the current investigation showed strong colocalization of BoNT/A-cleaved SNAP25 with several markers for MNs, not all the SNAP25 197 -IR signal in the VLSC was accounted for (Figure 6 ). It was clear from our neuronal tracing experiments using labeled-CTB that MNs have extensive dendritic arborization as previously demonstrated (Cook and Woolf, 1985; Kurz et al., 1990) . However, even with multiple injections of labeled-CTB within the same muscle, we were unable to trace the entire dendritic arbor of any given MN. In contrast, SNAP25 197 -IR staining showed a broader pattern of expression in the ipsilateral VLSC (Figure 8 ), as would be expected for the MN dendritic arborization in that region (Figure 1) . The discrepancy in expression between CTB and SNAP25 197 can be partially explained by differences in the intracellular trafficking patterns of these two proteins (see below).
The detection of the cleaved substrate is not necessarily a clear indication for the presence of the BoNT/A protease. Previous investigations have suggested that the appearance of SNAP25 197 in remote regions of the cell indicates the presence of active BoNT/A, although it was not clear whether this was the holotoxin or just the light chain (L C /A) portion (Antonucci et al., 2008; Matak et al., 2011; Matak et al., 2012; Restani et al., 2011; Restani et al., 2012b) . The presence of toxin in these studies was examined by a series of experiments, one of which in particular, provides support for the presence of active BoNT/A, or L C /A in distal terminals of treated neurons (Restani et al., 2011) . A separate study examining the movement of fluorescent-labeled BoNT/A holotoxin or heavy chain (H C /A) alone in MN microfluidic cultures, suggested that a small percentage of toxin underwent retrograde transport in non-acidic endosomes overlapping the same pathway used by tetanus neurotoxin (Restani et al., 2012a) .
However in that study, it was unclear whether the labeled holotoxin actually included the L C /A, or was simply the detached, labeled-H C /A undergoing transport to lysosomal bodies in the soma for degradation ).
An alternative explanation for the presence of SNAP25 197 is the potential for transport of the BoNT/A-cleaved substrate from the presynaptic terminal to other regions of the neuron (Zhang et al., 2016) . Studies have shown that SNAP25 is broadly distributed throughout the CNS and is especially enriched in neuronal axons, processes and terminals (Chen et al., 1999; Oyler et al., 1991) . Unlike other SNARE proteins which are anchored to the membrane by transmembrane domains, SNAP25 is bound tightly to the plasma membrane by a process of palmitoylation (Lane and Liu, 1997; Salaun et al., 2004) . This process serves not only to anchor SNAP25 to the synaptic terminal, but also as an active mechanism for intracellular trafficking and sorting of this protein to different lipid microdomains throughout the cell (Aikawa et al., 2006; Degtyar et al., 2013; Greaves and Chamberlain, 2011; Greaves et al., 2010) . Thus, SNAP25 itself may be dynamically regulated and shuttled to remote regions of the neuron even after cleavage by BoNT/A within the synaptic terminal, as SNAP25 197 should still retain the palmitoylation domain (Gonzalo et al., 1999) . Indeed, our data demonstrating SNAP25 197 -IR staining in all regions of the MN, especially along the motor nerve axon, and in a time-dependent manner suggests an active trafficking process for this protein.
The current study does not answer the question of whether or not BoNT/A (holotoxin or L C /A) undergoes retrograde transport within a neuron. While there is evidence supporting this hypothesis (Restani et al., 2011) , in order to definitively address the issue, one must follow the active enzymatic domain (L C /A) alone or in parallel with the labeled-binding domain (H C /A).
This can be performed either with site-specific antibodies or separate fluorescent tags for both ends of the toxin. However, such studies may be difficult to perform in rodent models given the small (picogram) amounts that must be administered. Nevertheless, whether BoNT/A or BoNT/A-cleaved SNAP25 can form stable, although non-functional SNARE complexes in neurons together with syntaxin, VAMP and potentially other uncleaved SNAP25 proteins (Bajohrs et al., 2004; Otto et al., 1995) . These faulty SNARE complexes have a prolonged life within the synaptic terminal, where they can create a dominant-negative effect on neurotransmitter release (Meunier et al., 2003; Montecucco and Molgo, 2005; 
Functional implications
Preclinical and clinical studies have demonstrated that BoNT/A-induced peripheral muscle paralysis can lead to minor functional changes within the CNS (Curra and Berardelli, 2009 ). In general these compensatory changes, which take place post-injection of spastic muscles help to improve overall muscle synchrony by influencing the spinal and cortical sensorimotor circuitry Kim et al., 2006; Marchand-Pauvert et al., 2013) . This reported shift in physiological activity of neurons synapsing onto BoNT/A-treated cells has been speculated to be a direct effect of BoNT/A via retrograde transport and transcytosis of the toxin Mazzocchio and Caleo, 2014) . Consequently, it was theorized that peripheral applications of BoNT/A may directly affect the CNS, despite the lack of supporting clinical evidence.
In light of data from the current study challenging this hypothesis, an alternative explanation is that SNAP25 197 , expressed as a dominant-negative in primary MNs may lead to temporary inhibition of central dendritic projections of the MNs, in addition to decreased activity at peripheral MNTs. This inhibition may result in compensatory responses from neighboring neurons, such as Renshaw cells, excitatory and inhibitory neurons, which rely on continuous feedback from MNs (Hall, 2004; Kiehn, 2006) . However, because these mechanisms fundamentally reside within the CNS, it can be incorrectly perceived as though these changes are a direct result of BoNT/A activity within second-order neurons (Curra and Berardelli, 2009 ).
According to our data and consistent with observations in cultured neurons (Lawrence et al., 2012) , functional inhibition of MNs at the dendritic level could potentially be observed following relatively high doses of BoNT/A, but not following lower, physiologically relevant doses.
CONCLUSIONS
Under the present experimental conditions, which included use of a highly selective antibody for the BoNT/A-cleaved substrate (SNAP25 197 ) combined with 3-dimensional imaging, we demonstrated that BoNT/A was confined to MNs after rat hindlimb injection. A high dose of BoNT/A, but not a lower dose, resulted in sporadic SNAP25 197 signal in distal muscles and associated SC regions without evidence for transcytosis, suggesting that the staining was due to systemic spread of toxin at high doses and not through transcytosis within the SC. This study did not resolve whether or not BoNT/A undergoes retrograde transport within a neuron. 
